FDA Grants Breakthrough Therapy Designation for KRAS Inhibitor Therapy

The FDA has granted Breakthrough Therapy designation to calderasib (MK-1084) plus KEYTRUDA, signaling rapid progress in KRAS Inhibitor Therapy for newly diagnosed patients with advanced KRAS G12C-mutant non-small cell lung cancer and PD-L1 expression of at least 1 percent.

This marks the first such designation for calderasib and is based on early data from the Phase 1 KANDLELIT-001 trial. The status offers intensive FDA guidance, rolling review, and possible Priority Review, accelerating development for a population with limited first-line options.

Prevalence and Clinical Need in Adenocarcinoma

KRAS G12C mutations appear in roughly 14 percent of non-small cell lung cancer cases with adenocarcinoma histology. The designation underscores the potential of KRAS Inhibitor Therapy to address a driver long considered difficult to drug.

Ad

KANDLELIT-001 results showed preliminary signs of substantial improvement over existing therapies on key endpoints. Calderasib’s profile as a potent, selective next-generation covalent inhibitor supports its use alongside anti-PD-1 therapy to disrupt cancer growth signals.

Broad Phase 3 Program Across Tumor Types

Development occurs through a collaboration with Taiho Pharmaceutical and Astex Pharmaceuticals. Five Phase 3 trials are now active, including KANDLELIT-004 and KANDLELIT-007 in lung cancer plus studies in colorectal cancer, all evaluating KRAS Inhibitor Therapy combinations.

Market Access Considerations for Precision Combinations

The designation may shorten timelines for health technology assessments and payer reviews. Stakeholders evaluating outcomes research and reimbursement will need to factor in the therapy’s specificity and first-line positioning once additional Phase 3 data become available.